Fulcrum Therapeutics(FULC) - 2024 Q2 - Quarterly Results

• Cash Position: As of June 30, 2024, cash, cash equivalents, and marketable securities were $273.8 million, as compared to$236.2 million as of December 31, 2023. The increase in our cash position is due to the $80.0 million upfront payment received from Sanofi in the second quarter of 2024, partially offset by cash used to fund our operating activities in 2024. • Collaboration Revenue: Collaboration revenue was$80.0 million for the three months ended June 30, 2024, as compared to $0.9 million for the thr ...